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Abstract 
Purpose: To further explore the effect of 5-aminosalicylic acid (5-ASA) treatment on lipid levels in mice 
fed different diets.  
Methods: Groups of 9 - 10 mice each were randomly assigned to 6 different diets, low-fat diet (LFD) 
with or without 5-ASA, high-fat diet (HFD) with or without 5-ASA, and high-fat high-cholesterol diet 
(HFC) with or without 5-ASA for 12 weeks.  
Results: There were changes in gut microbiota of 5-ASA-treated mice, although gut permeability was 
similar between treated and non-treated groups. The level of fasting blood glucose, fasting plasma 
insulin and the curve of glucose tolerance test (GTT) in mice fed LFD, HFD or HFC diet were not 
affected by 5-ASA treatment. Although plasma lipid levels were similar between 5-ASA consuming and 
non-5-ASA groups in mice fed LFD and HFD, improved lipid profile was seen in mice that received 
HFC+5-ASA when compared with mice fed only HFC.  
Conclusion: These results indicate that targeting gut inflammation and dysbiosis with 5-ASA neither 
improves gut barrier nor insulin resistance (IR). Thus, results from therapies for metabolic disorder 
based on anti-gut inflammation should be interpreted with caution. 
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Obesity is emerging as one of the most harmful 
global public health problem. The disease is 
associated with a series of metabolic 
complications, not only including insulin 
resistance (IR), but also type 2 diabetes (T2DM), 
dyslipidemia. Numerous studies show that 
systemic inflammatory reaction has a vital role in 
the early stage of obesity and promotes obesity-
associated complications [1-3]. Therefore, anti-
inflammatory scheme becomes as new 
treatments for metabolic disorders [4]. Although 
many preclinical studies support this opinor, 
results generated from clinical trials are quite 
controversial and still ongoing [5,6]. 
 
Several conditions lead to systemic inflammation, 
and in recent years, gut inflammation and 
gastrointestinal flora have attracted more 
attention than ever before due to their 
relationship with the immune system and IR. 
High fat diet (HFD) is reported to induce low-
grade intestinal inflammation and dysbiosis of gut 
microbiota [7,8]. Intestinal inflammation and 
dysbiosis are believed to be related to broken 
and dysfunction of the intestinal wall, which may 
activate and further prompt systemic IR. 
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Recently, a mice study suggested that targeting 
gut inflammation with 5-aminosalicylic acid (5-
ASA) reversed intestinal inflammatory response 
and improved systemic IR [9], but no data on 
lipid profile was presented [9]. 5-Aminosalicylic 
acid (5-ASA) is a notable agent which exert its 
anti-inflammation function mainly in the gut. 
Since metabolic abnormalities are strongly 
related to each other and are considered as 
independent risk factors to each other, the 
improvement of IR by 5-ASA treatment suggests 
that lipid levels may be affected as well. 
Moreover, taking non-steroidal anti-inflammatory 
drugs (NSAIDs) show benefits in hyperlipidemia, 
steatohepatitis and atherosclerosis [11]. In 
addition, cholesterol component of HFD is 
proved to be a potent intestinal inflammatory 
trigger [12]. 
 
The aim of the present study was to determining 
the role of intestinal inflammation in the 
pathogenesis and progression of diet-induced 
metabolic complications by studying metabolic 
parameters in mice fed low fat diet (LFD) with or 
without 5-ASA, high-fat diet (HFD) with or without 
5-ASA, high-fat, high-cholesterol diet (HFC) with 
or without 5-ASA. 
 
Although there are many studies that have 
targeted inflammation for the treatment of 
diabetes, the extent to which gut inflammation 
contributes to IR and dyslipidemia is still unclear, 
especially in mice challenged with high-fat, high-
cholesterol diet. To get more insight into this 
question in the present study, mice experiment 
was set up using the same diet composition as in 
the study by Luck et al. did [9]. C57BL/6J mice 
were then used in our experiments, randomly 
assigned 6 groups of mice to LFD or HFD or 
HFC with or without 5-ASA supplementation at 
1500 mg/kg/day for 12 weeks. Some IR-related 




Mice and treatment  
 
The mice experimental protocols were approved 
by the University of Groningen, the Ethical 
Committee for Animal Experiments (approval no. 
15246.2). And all experiments were carried out in 
accordance with the principles and guidelines 
generated and accepted by the European 
Convention which was aimed to protect and 
reduced the pain of Laboratory Animals [10]. 
Nine to ten male C57BL/6J mice, aged 10-12 
weeks, were considered as one group, and each 
mice was kept individually in the Individual 
ventilated cages and maintained at 23 °C, 50 % 
humidity, and 12h light/12h dark cycle.  
All the mice were able to access to food and 
water freely. They were randomly assigned to 6 
groups, each having 10 mice, and fed either low-
fat diet (LFD; the diet supplier is USA Research 
Diets, 10 % of energy coming from fat), LFD + 5-
ASA, high-fat diet (HFD; the diet supplier is USA 
Research Diets, 60 % of energy coming from fat 
), HFD+5-ASA, high-fat high-cholesterol diet 
(HFC; the diet supplier is USA Research Diets, 
60 % of energy coming from fat and plus 0.25 % 
cholesterol) or HFC+5-ASA for 12 weeks. 5-ASA 
powder (Sigma-Aldrich, USA) was mixed 
homogenously with LFD, HFD and HFC diets as 
appropriate, and presented at 1,500 mg/kg/day. 
 
Metabolic studies and tissue preparation 
 
Body weight as well as food intake were 
documented before diet interventions and 
recorded weekly after diet interventions were 
started. At the end of 12-weeks diet intervention, 
fat or lean mass was analyzed (the machine 
model is Bruker Minispec Whole Body 
Composition Analyzer). Fresh fecal samples 
were collected before treatment and after 3 
weeks of diet intervention to conduct gut 
microbiome sequencing [9] . 
 
Glucose tolerance test (GTT) was carried at 
week 11 with a 2 g/kg glucose i.p. injection [13]. 
Blood samples from the end of mice tail were 
collected in EDTA-coated tubes before and at 15, 
30, 60, 90, 120 minutes after i.p. injection. 
Samples were spun at 3000rpm for 10min at 4 
oC and insulin concentrations were measured in 
plasma using ELISA kit (Alpco Diagnositics, 




The biggest lope of liver from each mouse was 
taken and fixed in 4 % phosphate-buffered 
formalin overnight, then samples were 
embedded in liquid paraffin overnight. For 
microscopic examination, liver sample were 
sectioned by Leica paraffin slicing machine at 
4µm and hematoxylin and eosin (H&E) was used 
for staining. Representative photomicrographs 
were captured at 100× magnification using the 
software incorporated in the microscope (Leica 
DM 3000). 
 
Quantification of plasma and liver lipids 
 
Triglycerides and cholesterol levels of plasma or 
liver were determined by Roche kits (Roche; 
Germany), and free cholesterol was measured 
by DiaSys kit (FS DiaSys, Holzhein, Germany) 
[14]. 
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HPLC sample preparation 
 
Plasma 5-ASA and N-acetyl 5ASA were 
measured on a Waters HPLC system and 
Waters Empower software, consisting of a 
Waters 600 HPLC Pump, the model number is 
Waters 770 autosampler, Nova-Pak RP-C18 
column and a Waters 717 Fluorescence Detector 
(the detector setting is 317 nm excitation, and for 
emission cut off is 417 nm) [15]. 
 
Gut permeability assays 
 
The gut permeability assays were performed at 
the end of 12-weeks diet intervention. The 
gavage volumes of FITC-conjugated dextran 
(supplier company is Sigma, USA) were 
calculated by body weight, the final concentration 
is 0.4 mg/g body weight. After 4 hours of gavage, 
plasma fluorescence at 485/528 nm was 
measurement according to standard samples, 
the machine model is Synergy H1 Bio-tek [15]. 
 
Quantitative real-time PCR 
 
RNA samples were isolated using Qiazol 
reagent, the isolating protocol was established 
according to the Roche kit’s instructions. Roche 
Transcriptor Universal cDNA Master kit was 
selected to synthesize cDNA from RNA samples 
according to their instructions (Roche, 
Mannheim, Germany). Quantitative real-time 
PCR was done using SYBR Green Master Mix 
reagent (Roche) with an Applied Biosystems 
amplification machine (the machine model is 
7900HT). To reduce error, each sample was run 
in triplicate and PPIA housekeeping gene were 
used to normalized the genes expression. 
Relative fold changes in gene expression 
normalized to itself’s PPIA gene were then 
analyzed by the ΔΔCT method (the concrete 
equation is 2-ΔΔCT). The results of calculation 
using above method are presented as fold 
changes relative to the transcript levels of the 
control. The following primers were used to verify 
the expression of the target genes: PPARγ: 
forward, GCCCTTTGGTGACTTTATGG, reverse, 




reverse, CCGCCAGTGCCATTATGG [15]. 
 
Statistical analysis  
 
Mean ± standard error of the mean (SEM) were 
present to show the data obtained in study. For 
comparisons between two groups, Student’s t-
tests was used for calculation. And for 
comparisons of 3 groups or more than 3 groups, 
one-way analysis of variance (ANOVA) was used 
for the statistical analyses. All analyses were 
performed using GraphPad Prism 5. To show the 
statistically significant results, P < 0.05 was 




5-ASA treatment did not affect metabolic 
basic parameters and IR-related factors in 
mice  
 
After a 12-week diet intervention, mice fed HFD 
or HFC diet gained much more body weight as 
well as body fat mass than those in LFD group 
(Figure 1A, B). However, mice fed LFD or HFD 
or HFC diet did not show significant differences 
in body composition (Figure 1B) and food intake 
(Figure 1C) when compared with the 5-ASA 
treated and non-treated groups. 
 
In order to investigate whether 5-ASA improves 
systemic IR in mice fed HFD and to test if 5-ASA 
improves these parameters when mice are fed 
HFC diet, GTT was carried out after 11 weeks of 
dietary intervention. Compared to mice assigned 
to LFD group, the HFD and HFC groups 
displayed remarkably higher fasting blood 
glucose levels (Figure 2A) while performing GTT 
(Figure 2C). Surprisingly, contrary to previous 
reports, mice treated with 5-ASA showed similar 
fasting glucose (Figure 2A), fasting insulin 
(Figure 2B) and glucose tolerance (Figure 2C) 
irrespective of diet. These results suggest that 5-
ASA has no remedial effects on the metabolic 
and homeostasis of glucose in diet-induced 
obesity. 
 
5-ASA treatment improved lipid level in mice 
fed on HFC diet  
 
Although reduced liver steatosis showed by H&E 
staining in the HFD 5-ASA group by Luck et al 
seemed rather attractive, their study did not 
involve quantitative measurement of plasma and 
hepatic lipid levels. Treatment with 5-ASA did not 
affect liver weight in mice fed LFD, HFD or HFC 
diet (Figure 3A). Results from histology showed 
no obvious differences in lipid accumulation 
between 5-ASA-treated mice and those that did 
not receive 5-ASA (result not shown). However, 
analysis of liver lipid profile showed a mild but 
significant reduction in triglycerides (Figure 3B), 
but not in total and free cholesterol (Figures 3C 
and Figure 3D) in the 5-ASA treated mice, when 
compared to HFC-fed mice without 5-ASA 
exposure.
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Figure 1: Effect of 5-ASA treatment on body composition and food intake of mice. Note: (A) Body weights of 
mice fed on different diets over time, *p < 0.05 vs. LFD. (B) Fat or lean mass of mice after 12 weeks on different 
diets. *p < 0.05 vs. LFD; #p < 0.05 vs. LFD+5-ASA. (C) Food intake of mice fed on different diets in the first week 
and 11th week. Data obtained here are showed as mean ± SEM, n = 9-10 mice 
 
 
Figure 2: Effect of 5-ASA treatment on IR-related metabolic parameters in mice. Note: (A) Fasting glucose, (B) 
fasting insulin and (C) GTT of mice fed different diets for 12 weeks. *p < 0.05 vs. LFD; #p < 0.05 vs. LFD 5-ASA. 
Data obtained here are showed as mean ± SEM, n = 9-10 mice 
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Relative to LFD groups, HFD or HFC exposure 
for 12 weeks did not affect plasma triglycerides 
(Figure 3E), but it significantly elevated plasma 
total cholesterol and free cholesterol (Figure 3F 
and Figure G). In HFD and HFC groups, 5-ASA 
treatment led to a downward trend in plasma 
total cholesterol and free cholesterol (Figure 3F 
and Figure G). Interestingly, mice fed on LFD + 
5-ASA showed lower triglyceride level than those 
fed LFD (p = 0.052). Mice in the HFC 5-ASA 
group had significantly attenuated plasma 
triglyceride when compared to the HFC group 
(Figure 3E). However, cholesterol levels were not 
affected by 5-ASA in any of the diets (Fig. 3F and 
G). These data suggest that 5-ASA may act as a 
lipid regulator especially when mice are 
challenged with a HFC diet. 
 
Effect of 5-ASA on small intestine  
 
There were no traces of 5-ASA and its 
metabolites in circulation (Figure 4A). This 
confirms the functionalization of 5-ASA in small 
intestine through the up regulation of mRNA 
expression of its target gene, which is also well 
accepted to be the anti-inflammatory target, 
peroxisome proliferator-activated receptor-γ 
(PPARγ, Figure 4B). After 3 weeks of treatment, 
5-ASA induced significant changes in gut 
microbial flora when compared to HFD and HFC 
diet (data not shown). However, results of 
fluorescence FITC-dextran 4 (FD4) assay 
showed that 5-ASA treatments did not improve 
intestinal epithelial barrier permeability (Figure 
4C) irrespective of diet used. This is consistent 
with the results related to glucose homeostasis. 
 
Since PPARs (including PPARγ and PPARα) are 
generally considered as master regulators of lipid 
homeostasis, studies were carried out to 
determine whether the lipid lowering effect of 5-
ASA was associated with PPARα. The results 
revealed that the expression of PPARα mRNA in 
small intestine in mice fed HFC + 5-ASA was 
significantly higher than in mice fed HFC only 
(Figure 4D). Similar results were seen for the 
downstream target genes of PPARα, such as 
HSL, AOX and CTP1α, which play roles in 
lipolysis and fatty acid oxidation (data not 
shown). 
 
Figure 3: Effect of 5-ASA on lipid profile in mice fed either LFD, HFD or HFC diet. Note: (A) Liver weight of mice 
after 12 weeks feeding of different diets. (B-D) Liver triglycerides, total cholesterol and free cholesterol 
concentrations of mice after 12 weeks dietary. (E-G). *p < 0.05 vs. LFD; #p < 0.05 vs. LFD+5-ASA; & p < 0.05 vs. 
HFC+5-ASA. Data obtained here are showed as mean ± SEM, n = 9 to 10 mice 
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Figure 4: Effect of 5-ASA on small intestine. Note: (A) 5-ASA and its metabolites concentration in plasma after 3 
weeks of diet intervention. Values are mean ± SEM, n = 4-5 mice. (B) PPARγ mRNA expression relative to PPIA, 
which is the housekeeping gene expression in small intestine of mice after 12 weeks dietary intervention; *p < 
0.05 vs. HFC. (C) Plasma FD4 levels, measured at 4 hours after oral gavage of mice at the end of 12 weeks of 
diet intervention. (D) PPARα mRNA expression relative to PPIA, which is the housekeeping gene expression in 




Improved understanding claimed obesity-related 
complications are characterized and advanced 
by chronic low-grade inflammation, and target 
inflammation may block the development of 
chronic metabolic syndromes such as IR and 
dyslipidemia [17-19]. Although anti-inflammatory 
agents show some beneficial outcomes in animal 
studies and clinical trials [4,5,20]. Systemic anti-
inflammatory therapies are not ideal since 
inflammatory response is rather critical for host 
defense. Moreover, anti-inflammation may lead 
to serious side effects. Indeed, studies from 
animal and human suggest inflammation in 
obesity is not always deleterious, while results 
from many studies are controversial [6]. 
 
Recently, people proved HFD induced gut 
inflammation and then triggers metabolic 
disorders while anti-enteritis agent, 5-ASA 
reverses IR through improvement of fasting 
blood glucose, insulin levels and glucose 
tolerance [21]. These are at variance with the 
data acquired in this study, which showed that 5-
ASA treatment did not have a specific effect on 
fasting blood glucose levels, fasting plasma 
insulin levels and GTT response in mice fed 
either LFD, HFD or HFC. This finding indicates 
that associations between gut anti-inflammatory 
agent and IR should be interpreted with caution.  
 
Additionally, HFD+5-ASA-fed mice showed 
reduced liver steatosis when compared to HFD 
[9]. A similar downtrend in hepatic and plasma 
lipid levels in mice given 5-ASA+HFD, especially 
in mice fed HFC. 5-ASA shares many of the 
pharmacological properties of non-steroidal anti-
inflammatory drugs (NSAIDs), for instance 
aspirin. Intake of aspirin resulted in decreased 
serum total cholesterol and triglycerides in 
patients [22] while chronic administration of 
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NSAIDs is effective in preventing steatohepatitis 
and atherosclerosis in mice fed HFD [11]. These 
findings reveal the function of systemic and 
intestinal inflammation in the pathogenesis and 
progress of diet-induced dyslipidemia. However, 
the results showed here indicated that the lipid-
modulatory effect of 5-ASA may be independent 
of its effect on IR. 
 
5-ASA is widely used in the therapeutic and 
maintenance treatment of IBD and is among the 
oldest anti-inflammatory agents in use today. 
Although the exact mechanisms of action of 5-
ASA are not completely elucidated, recent 
studies have revealed that multiple intestinal anti-
inflammatory effects of 5-ASA rely on increased 
expression of PPARγ; As a receptor of 5-ASA 
[23,24], PPARγ and PPARα not only act 
effectively as anti-inflammatory targets, but also 
a major lipid sensors that control the expression 
of genes related to lipid and carbohydrate 
metabolism [25]. The present study reports that 
the lipid-lowering effect of 5-ASA is associated 
with enhanced PPARs and the function of their 
downstream target genes in fatty acid oxidation 
in the small intestine for the first time and more 
experiment was urgent needed to further 




The present study explored the role of gut 
inflammation in the pathogenesis of diet-induced 
metabolism disorders. The findings show that 
targeting intestinal inflammation does not result 
in obvious improvement of IR parameters. 
However, 5-ASA treatment is associated with a 
lipid-lowering effect in mice fed HFC diet, and 
this effect is related to the activation of PPARs in 
gut. Overall, it is rather promising that gut 
inflammation may serve as a distinct target in 
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